Guardant Health Liquid Biopsy – Early Stage Colorectal Cancer

Dr. Kathryn Lang, vice president of Health Outcomes and Evidence at Guardant Health discusses research highlighting the significance of its LUNAR-2 liquid biopsy test in detecting early-stage colorectal cancer (CRC) with clinically meaningful accuracy. These data were presented during the American Cancer Association for Cancer Research (AACR) Virtual Meeting II in Abstract #2316: “Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer”.

Read More

GuardantINFORM™ Platform

Daniel Simon discusses the GuardantINFORM™ platform featuring an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients. The platform is intended to help accelerate research and development of the next generation of cancer therapeutics by offering biopharma partners an in-silico platform that combines de-identified longitudinal clinical information and genomic data collected from the Guardant360® liquid biopsy test —over 100,000 tests to date.

Read More

Beyond the visible – Rosacea and Psoriasis of the Face

Galderma’s “Beyond the visible: rosacea and psoriasis of the face” is a global survey involving over 600 patients with facial skin disease (rosacea or psoriasis) and 361 doctors across 6 countries.  Here to discuss the findings of the survey and the burden on patients’ productivity and daily lives is one of the report authors, board-certified dermatologist and Galderma consultant, Dr. Julie Harper. 

Read More

Racial Disparities in Healthcare

Dr. Imamu Tomlinson, CEO of Vituity and a practicing emergency physician, discusses his own experience with discrimination as a Black American and how it has influenced his approach to leadership and medicine.  He talks about conversations he has had with his physician teams about racial injustice, the role of healthcare in serving as an equalizer, and the impact healthcare access can have on bringing justice to local communities.

Read More

Prealize – Precision Healthcare

Linda Hand, CEO of Prealize, discusses the use of AI and machine learning to pinpoint individuals and populations most likely to have a significant health event over the next 12-18 months that will benefit from early intervention. She also talks about the post-pandemic healthcare surge and precision public health.

Read More

American Council on Exercise (ACE) – Mover Method™

Dr. Cedric Bryant, Ph.D., Chief Science Officer at the American Council on Exercise (ACE) discusses ACE’s behavior change research-based philosophy called the Mover Method™ which ACE believes can have a measurable impact on public health. He also talks about health equity and how some of ACE’s exercise professionals work and live in communities where lifestyle-related diseases like diabetes/heart disease are most prevalent and he is working with organizations like the World Health Organization and the CDC to find solutions for these lifestyle diseases. 

Read More